Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

December 15th 2022

Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.

Trastuzumab Deruxtecan sNDA for HER2-Mutant Metastatic NSCLC Submitted for Review in Japan

December 15th 2022

Daiichi Sankyo has filed a supplemental new drug application with Japan’s Ministry of Health, Labor, and Welfare for the use of fam-trastuzumab deruxtecan-nxki in adults with previously treated HER2-mutant unresectable advanced or recurrent non–small cell lung cancer.

Dr. Mercado on the Effect of the COVID-19 Pandemic on Lung Cancer Screening

December 14th 2022

Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.

FDA Approves ctDx FIRST as Liquid Biopsy Companion Diagnostic Test for Adagrasib in Advanced NSCLC

December 14th 2022

The FDA has issued an accelerated approval for the Agilent Resolution ctDx FIRST assay for plasma as a companion diagnostic for adagrasib.

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC

December 12th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

FDA Approves Adagrasib for Locally Advanced or Metastatic KRAS G12C+ NSCLC

December 12th 2022

The FDA has granted accelerated approval to adagrasib (Krazati) for the treatment of adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, as determined by an FDA-approved test, who have received at least 1 prior systemic therapy.

Dr. Patel on Key Updates from First-Line Trials in NSCLC

December 9th 2022

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

December 9th 2022

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

December 9th 2022

A focused review of data from the POSEIDEN post-hoc analysis in patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated non–small cell lung cancer.

Understanding the Nature of a KRAS G12C Mutation in NSCLC

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

Neoadjuvant Nivolumab Plus Chemotherapy Bests Nivolumab Alone in Resectable NSCLC

December 9th 2022

Neoadjuvant treatment with nivolumab (Opdivo) plus platinum doublet chemotherapy showed superior major pathological response rates and pathological complete response rates compared with nivolumab monotherapy among patients with resectable non–small cell lung cancer even for patients with a PD-L1 expression of 50% or greater.

Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

December 9th 2022

Expert oncologists Melissa Johnson, MD, and Joshua Sabari, MD, discuss the occurrence of individual KRAS, STK11, or KEAP1 mutations in patients with non–small cell lung cancer and if there is a role for immunotherapy in the treatment of these patients.

Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis

December 8th 2022

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

Frontline Adagrasib Plus Pembrolizumab Elicits Encouraging Clinical Activity in KRAS G12C+ Advanced NSCLC

December 8th 2022

Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.

Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC

December 8th 2022

Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.

Dr. Patel on Choosing a Chemoimmunotherapy Treatment in NSCLC

December 6th 2022

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Sintilimab Plus Anlotinib Improves Responses, PFS Vs Chemotherapy in Untreated NSCLC

December 5th 2022

The combination of sintilimab and anlotinib elicited improved responses and progression-free survival compared with chemotherapy in previously untreated patients with metastatic non–small cell lung cancer.

EMA Accepts Marketing Authorization Application for Aumolertinib in EGFR-Mutated NSCLC

December 2nd 2022

Pharmaceutical manufacturer EQRx announced December 2, 2022, that the European Medicines Agency has accepted a marketing authorization application for the use of aumolertinib in EGFR-mutated non–small cell lung cancer and locally advanced or metastatic EGFR T790M mutation–positive NSCLC.

Novel Antibody-Drug Conjugates May Provide Effective and Targeted Treatment for NSCLC

December 2nd 2022

Stephen V. Liu, MD, highlights the advantages of antibody-drug conjugates in lung cancer treatment, the current landscape of antibody-drug conjugate development, and several questions and considerations for continued investigation.

NEOpredict-Lung Data Support the Addition of Relatlimab to Preoperative Nivolumab in Resectable NSCLC

December 1st 2022

Evan J. Lipson, MD, expands on key takeaways from the NEOpredict-Lung trial, the additional benefit that PICIT may offer to patients who progress on other immunotherapies, and the effect that both NEOpredict-Lung and RELATIVITY-047 have on the role of immunotherapy in the lung and melanoma treatment paradigms.